Uses of Evoflo Evohaler 25/50mcg

Evoflo Evohaler contains the main active ingredients Salmeterol 25 micrograms and fluticasone propionate 50 micrograms. The drug is prepared in the form of a mist suspension for inhalation through the mouth. One spray bottle contains 120 spray doses. Salmeterol is a long-acting beta 2 receptor agonist that relaxes bronchial smooth muscle and prevents symptoms of asthma and chronic obstructive pulmonary disease. Fluticasone propionate is an inhaled corticosteroid with effective anti-inflammatory properties. In general, Evoflo Evohaler is indicated in the treatment of bronchial asthma and COPD.
Asthma: Evoflo Evohaler is indicated for asthmatic patients on effective treatment with maintenance doses of long-acting beta-agonists and inhaled corticosteroids; the patient remains symptomatic while being treated with inhaled corticosteroids; The patient is on regular treatment with a bronchodilator and requires inhaled corticosteroids. Chronic Obstructive Pulmonary Disease (COPD): Evoflo Evohaler is indicated in the routine treatment of chronic obstructive pulmonary disease including chronic bronchitis and emphysema. The drug has been shown to reduce all-cause mortality in patients with COPD.

Asthma :
Adults and adolescents 12 years of age and older: Use two sprays of 25 micrograms salmeterol and 50 micrograms fluticasone propionate, twice daily; or two sprays of 25 micrograms salmeterol and 125 micrograms fluticasone propionate, twice daily; or two sprays of 25 micrograms salmeterol and 250 micrograms fluticasone propionate, twice daily. Children 4 years and older: Use two sprays of 25 micrograms salmeterol and 50 micrograms fluticasone propionate, twice daily. There are no data on the use of Salmeterol/Fluticason propionate in children under 4 years of age. Chronic Obstructive Pulmonary Disease (COPD): The recommended dose of Evoflo Evohaler for adult patients is two sprays of 25/125 micrograms to 25/250 micrograms salmeterol/fluticasone propionate twice daily.

Evoflo Evohaler 25/50mcg is contraindicated in patients with known hypersensitivity to any of the ingredients.

Patients using Evoflo Evohaler 25/50mcg may experience unwanted effects including:
Infections and parasitic infections: Oral and pharyngeal candidiasis, pneumonia (in patients with lung disease) chronic obstruction). Immune system disorders: Hypersensitivity reactions, dyspnea, anaphylactic reactions. Endocrine disorders: Cataracts, glaucoma. Metabolic disorders: Hyperglycemia. Psychiatric disorders: Anxiety, sleep disturbances, behavioral changes, including hyperactivity and agitation (mainly in children) Nervous system disorders: Headache, tremor. Cardiovascular disorders: Palpitations, tachycardia, atrial fibrillation, arrhythmia. Respiratory disorders: Hoarseness/hoarseness, throat irritation. Skin and subcutaneous tissue disorders: Bruises. Musculoskeletal and connective tissue disorders: Cramps, arthralgia.

Evoflo Evohaler is not intended for acute symptomatic relief, in which case the patient requires a quick and short acting bronchodilator (eg salbutamol). It is recommended that patients always have symptom relief medication with them at all times. Increased use of short-acting bronchodilators for symptom relief indicates deterioration in disease control and the patient should be reevaluated. Patients should also be re-examined when the current dose of Evoflo Evohaler does not provide adequate symptom control. Treatment with Evoflo Evohaler should not be stopped abruptly in asthmatic patients due to the risk of exacerbations, dose reductions should be made under the supervision of a physician. For patients with COPD, abrupt discontinuation of drug therapy may cause symptomatic decompensation and should be monitored by a physician. Pneumonia has been reported in studies with COPD patients receiving Salmeterol/Fluticason propionate. Attention should be paid to the possibility of pneumonia in patients with COPD because the clinical signs of pneumonia and exacerbations often overlap and are difficult to distinguish. Evoflo Evohaler should be used with caution in patients with thyrotoxicosis. Cardiovascular side effects such as increased blood pressure and increased heart rate may occasionally occur, especially when higher than therapeutic doses are used. Therefore, caution should be exercised when Evoflo Evohaler is administered to patients with pre-existing cardiovascular disease. Systemic side effects can occur with inhaled corticosteroids, especially when used in high doses for long periods, but the risk is much lower than with oral corticosteroids. Systemic side effects may include Cushing's syndrome, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, etc. Therefore, for asthmatic patients, it is important It is important to adjust the dose of inhaled corticosteroid to the lowest dose that maintains effective disease control. A transient decrease in serum potassium concentration may occur when Evoflo Evohaler is administered at higher than therapeutic doses. Therefore, caution should be exercised when Evoflo Evohaler is administered to patients who are susceptible to hypokalemia. Pregnancy and breast-feeding: Evoflo Evohaler should only be used by pregnant women and nursing mothers if the potential benefit outweighs the potential risk.

Concomitant use of Evoflo Evohaler with certain drugs may alter the therapeutic effect and/or increase the side effects of the drug. Under normal conditions, due to high cytochrome P450 3A4-mediated metabolism, low plasma concentrations are achieved after inhalation. Therefore, clinically significant drug interactions of Evoflo Evohaler are rarely encountered. However, when using the drug, patients should be aware of a number of possible interactions including:
Concomitant use of selective and non-selective beta-blockers should be avoided unless there is compelling reason. A drug interaction study in healthy subjects showed that ritonavir (a potent cytochrome P450 3A4 inhibitor) can cause high plasma concentrations of fluticasone propionate, resulting in a significant decrease in serum cortisol concentrations. . Clinically significant drug interactions have been reported in patients receiving inhaled nasal or oral fluticasone propionate and ritonavir resulting in systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. Concomitant use of fluticasone propionate and ritonavir should therefore be avoided unless the benefit outweighs the risk of systemic side effects. Other studies have shown that other Cytochrome P450 3A4 inhibitors produce a negligible (erythromycin) and a slight (ketoconazole) increase in systemic fluticasone propionate concentrations and no significant reduction in serum cortisol. However, patients should still be cautious when combining potent cytochrome P450 3A4 inhibitors with Evoflo Evohaler. The article has provided general information about the uses, side effects and notes during the use of Evoflo Evohaler. The information above is for reference only and cannot completely replace the guidance of medical personnel. Patients should consult their doctor or pharmacist before using the drug.